<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03451045</url>
  </required_header>
  <id_info>
    <org_study_id>JBT101-CF-002</org_study_id>
    <nct_id>NCT03451045</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corbus Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Corbus Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 multicenter, double-blind, randomized, placebo-controlled study assessing
      the efficacy and safety of lenabasum for the treatment of cystic fibrosis in patients 12
      years of age or older. Approximately 415 subjects will be enrolled in this study at about 100
      sites in North America, Europe, and Australia. The planned duration of treatment with study
      drug is 28 weeks.

      Study drug will be lenabasum 20 mg BID, lenabasum 5 mg BID, and placebo in a 2:1:2 ratio.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2017</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, double-blind, randomized, placebo-controlled, parallel group study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary Exacerbation (PEx)</measure>
    <time_frame>Visit 1 through Week 28.</time_frame>
    <description>Rate of PEx using the primary PEx definition with lenabasum 20 mg BID compared to placebo, during the treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Exacerbation (PEx)</measure>
    <time_frame>Visit 1 through Week 28.</time_frame>
    <description>Event rate of PEx using the secondary PEx definition with lenabasum 20 mg BID compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Exacerbation (PEx)</measure>
    <time_frame>Visit 1 through Week 28.</time_frame>
    <description>Time to first new PEx using the primary PEx definition with lenabasum 20 mg BID compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Exacerbation (PEx)</measure>
    <time_frame>Visit 1 through Week 28.</time_frame>
    <description>Time to first PEx using the secondary PEx definition with lenabasum 20 mg BID compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Exacerbation (PEx)</measure>
    <time_frame>Visit 1 through Week 28.</time_frame>
    <description>Event rate of PEx using the primary PEx definition with lenabasum 5 mg BID compared to placebo, during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Exacerbation (PEx)</measure>
    <time_frame>Visit 1 through Week 28.</time_frame>
    <description>Event rate of PEx using the secondary PEx definition with lenabasum 5 mg BID compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Exacerbation (PEx)</measure>
    <time_frame>Visit 1 through Week 28.</time_frame>
    <description>Time to first new PEx using the primary PEx definition with lenabasum 5 mg BID compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Exacerbation (PEx)</measure>
    <time_frame>Visit 1 through Week 28.</time_frame>
    <description>Time to first PEx using the secondary PEx definition with lenabasum 5 mg BID compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CFQ-R respiratory symptom domain</measure>
    <time_frame>Visit 1 through Week 28.</time_frame>
    <description>Change from baseline in CFQ-R respiratory symptom domain with lenabasum compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 % predicted</measure>
    <time_frame>Visit 1 through Week 28.</time_frame>
    <description>Change from baseline in FEV1 % predicted with lenabasum compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Visit 1 through Week 28.</time_frame>
    <description>Incidence of treatment emergent adverse events with lenabasum treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">415</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Lenabasum 20 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenabasum 5 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenabasum 20 mg</intervention_name>
    <description>Subjects will receive lenabasum 20 mg twice daily.</description>
    <arm_group_label>Lenabasum 20 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenabasum 5 mg</intervention_name>
    <description>Subjects will receive lenabasum 5 mg twice daily.</description>
    <arm_group_label>Lenabasum 5 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo twice daily.</description>
    <arm_group_label>Placebo BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 12 years of age at the time Informed Consent/ Assent is signed.

          2. Weight ≥ 40 kg.

          3. FEV1 ≥ 40% predicted and &lt; 100% predicted in the last 12 months.

          4. Physician-initiated treatment with an IV antibiotic 2 or 3 times in the last 12 months
             for a new PEx or physician-initiated treatment with an IV antibiotic 1 time in the
             last 12 months plus physician-initiated treatment with oral antibiotic(s) 1 or more
             times in the past 12 months for a new PEX.

        Exclusion Criteria:

          1. Severe or unstable CF at screening or Visit 1.

          2. Any of the following values for laboratory tests at screening:

               1. A positive pregnancy test.

               2. Hemoglobin &lt; 10 g/dL in males and &lt; 9 g/dL in females.

               3. Neutrophils &lt; 1.0 x 10^9 /L.

               4. Platelets &lt; 75 x 10^9/L.

               5. Creatinine clearance &lt; 50 mL/min according to Modification of Diet in Renal
                  Disease (MDRD) Study equation.

               6. Serum transaminases &gt; 2.5 x upper limit of normal.

          3. Any medical condition or concurrent medical therapies at screening or Visit 1 that may
             put the subject at greater safety risk, influence response to study drug or interfere
             with study assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Chmiel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rainbow Baby and Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Stuart Elborn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart and Lung Institute, Imperial College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lindsey Smith</last_name>
    <phone>617-977-5030</phone>
    <email>CFpatients@corbuspharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Scott Constantine, MS</last_name>
    <phone>617-977-5030</phone>
    <email>CFpatients@corbuspharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Verano</last_name>
      <phone>303-398-1808</phone>
    </contact>
    <investigator>
      <last_name>Steven Lommatzsch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore LIJ Health System</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janis Wang, MD</last_name>
      <phone>516-465-5427</phone>
    </contact>
    <contact_backup>
      <last_name>Andrea Sookchan</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Spears</last_name>
      <phone>846-792-2072</phone>
    </contact>
    <investigator>
      <last_name>Patrick A Flume, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2018</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary exacerbation, lenabasum, JBT-101</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

